

To: All Canadian Pharmacies, Hospitals, Regional Cancer Centres, Oncologists and Gastroenterologists
 Re: **PURINETHOL® (mercaptopurine tablets USP) Supply Update**

Please find below an update to our June 27, 2012 letter concerning the Canadian supply of **PURINETHOL® (mercaptopurine tablets USP)**.

With your support, we have been able to manage our inventory levels and maintain a consistent supply of product to the patients that need it most. We continue to work closely with our third party supplier in the U.S. as they resolve their production issues and in the meantime, have been collaborating with Health Canada to ensure a continuous supply of mercaptopurine for patients that rely on this medication.

Additional Inventory

As existing inventories are being reduced for Purinethol®, we have secured a temporary supply of Teva US Mercaptopurine intended for the US market. Under Health Canada’s Special Lot Release Program we were granted approval for **Lots #A74283C and # A71944D, Expiry May/2013**. This Teva US Mercaptopurine is deemed equivalent to the Canadian PURINETHOL® product by Health Canada; therefore the same DIN (Drug Identification Number) is used.

Product Appearance, Packaging, Patient Information Leaflet and DIN:

Teva US Mercaptopurine (produced for the U.S. market) is identical to Canadian Purinethol® except for the markings on the tablets and packaging as can be seen below:



Teva US Mercaptopurine is packed in FDA approved plastic bottles of 60 tablets instead of Health Canada approved glass bottles of 25 tablets for Purinethol®.

Additionally, a Teva Canada Patient Information Leaflet for Purinethol® in both English and French will accompany the product. Since the products are considered identical, Health Canada is permitting us to release the product using the Canadian approved Purinethol® leaflet; however since Teva US Mercaptopurine was already packaged for the US market, the Teva US leaflet is also affixed to the bottles. As the DIN is consistent with our existing product, reimbursement through Provincial Formularies will still be possible.

Direct Ordering & Shipping

To extend existing product supply for as long as possible, inventory will continue to be designated to priority patients. As such, Teva Canada will direct ship PURINETHOL® (mercaptopurine) to the pharmacy market across Canada. (This includes critical care facilities, hospitals and cancer treatment centres.)

**All orders for PURINETHOL® (mercaptopurine) are to be placed through:
 Teva Canada Customer Care Centre: TEL 1-800-268-4129 | FAX 1-800-387-4733**



September 11, 2012 | **SENT VIA EMAIL**

Long Term Supply

Although the number of manufacturers of PURINETHOL® (mercaptopurine) is very limited (with no active manufacturers in Canada), we have identified an alternate manufacturer, and have initiated the process to qualify this site for Canadian product manufacturing.

Thank you for your ongoing support and understanding. Please contact Teva's Customer Care Centre if you have any questions or concerns that are not addressed in this update.

Sincerely,

A handwritten signature in green ink, appearing to read "Barry Fishman".

Barry Fishman
President & CEO